Drug cocktail aims to shrink Hard-to-Treat stomach cancers

NCT ID NCT04164979

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining two drugs—cabozantinib and pembrolizumab—can slow or stop the growth of advanced gastric or gastroesophageal cancer. The study enrolls people whose cancer has worsened despite at least one prior chemotherapy treatment. Researchers will measure how many participants remain progression-free after six months and track any serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cabozantinib combined with pembrolizumab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced gastric cancer who have run out of standard chemotherapy options.
What could go wrong
This is an early-phase, single-arm trial with only 34 participants, so results may not be definitive. Combining two drugs also raises the risk of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chao Family Comprehensive Cancer Center, University of California, Irvine

    Orange, California, 92868, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.